SCHEMBL26426327

SCHEMBL26426327

CNc1cc(F)ccc1NC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ4 P56696 3/20 0.50
KCNQ5 Q9NR82 3/20 0.50
CYP17A1 P05093 2/20 0.44
RXFP1 Q9HBX9 1/20 0.41
HPGD P15428 1/20 0.39
HTT P42858 2/20 0.39
CTSS P25774 2/20 0.38
CTSK P43235 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
BRD9 Q9H8M2 1/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857284 0.84 HTT (0.55) KCNQ4KCNQ5CYP17A1HTTLMNA
SCHEMBL15614546 0.84 MAPT (0.51) KCNQ4KCNQ5CYP17A1RXFP1HTT
SCHEMBL5800267 0.83 KCNQ4 (0.51) KCNQ4KCNQ5CYP17A1RXFP1HTT
SCHEMBL8292291 0.83 KCNQ4 (0.48) KCNQ4KCNQ5CYP17A1HTTLMNA
SCHEMBL27398698 0.83 MAPT (0.51) KCNQ4KCNQ5RXFP1HPGDHTT
SCHEMBL21251511 0.82 KCNQ4 (0.48) KCNQ4KCNQ5CYP17A1RXFP1HPGD
SCHEMBL23954504 0.82 KMT2A (0.47) KCNQ4KCNQ5HPGDGAAMEN1
SCHEMBL197145 0.82 HDAC1 (0.55) KCNQ4KCNQ5CYP17A1HTT
SCHEMBL22092641 0.82 KCNQ4 (0.47) KCNQ4KCNQ5CYP17A1RXFP1HTT
SCHEMBL29581478 0.82 HDAC1 (0.55) KCNQ4KCNQ5CYP17A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 US disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 EP disclosed
CN-118556059-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-08-27 CN disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA KCNQ4 2200/4885KCNQ5 1867/4885CYP17A1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.